Regulation of adenosine receptor engagement by ecto-adenosine deaminase

被引:53
作者
Hashikawa, T
Hooker, SW
Maj, JG
Knott-Craig, CJ
Takedachi, M
Murakami, S
Thompson, LF
机构
[1] Oklahoma Med Res Fdn, Immunobiol & Canc Res Program, Oklahoma City, OK 73104 USA
[2] Osaka Univ, Grad Sch Dent, Dept Periodontol, Suita, Osaka 5650871, Japan
[3] Oklahoma Univ Hlth Sci Ctr, Dept Surg, Oklahoma City, OK USA
基金
日本学术振兴会;
关键词
CD26; cAMP; CD73;
D O I
10.1096/fj.03-0011fje
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Adenosine deaminase (ADA) can localize to the cell surface through its interaction with CD26. Using CD26-transfected cells, we demonstrate that cell surface ADA (ecto-ADA) can regulate adenosine receptor engagement by degrading extracellular adenosine (Ado) to inosine. This ability was dependent upon CD26 expression, the extent of CD26 saturation with ecto-ADA, and the kinetics of the cAMP response. Thus, the cAMP response was markedly decreased when CD26-transfected cells were incubated with an exogenous source of ADA to increase ecto-ADA expression. The ability of ecto-ADA to inhibit the cAMP response was demonstrated by treatment with the specific ADA inhibitor 2'-deoxycoformycin. This inhibited the ability of ecto-ADA to degrade Ado and increased the cAMP response. Although CD26 expression on human thymocytes was low compared with that of CD26-transfected cells, it was saturated with ecto-ADA. When thymocytes incubated at high densities (to mimic the situation in tissues) were exposed to exogenous adenosine, the cAMP response was dramatically decreased by ecto-ADA. We conclude that ecto-ADA has the potential to regulate adenosine receptor-mediated cAMP responses in vivo in tissues with CD26(+) cells and sufficient cell death caused by apoptosis or inflammation to provide a source of ADA to bind to CD26.
引用
收藏
页码:131 / 133
页数:3
相关论文
共 41 条
[1]   GENOMIC ORGANIZATION, EXACT LOCALIZATION, AND TISSUE EXPRESSION OF THE HUMAN CD26 (DIPEPTIDYL PEPTIDASE-IV) GENE [J].
ABBOTT, CA ;
BAKER, E ;
SUTHERLAND, GR ;
MCCAUGHAN, GW .
IMMUNOGENETICS, 1994, 40 (05) :331-338
[2]   TIGHT-BINDING INHIBITORS .4. INHIBITION OF ADENOSINE DEAMINASES BY VARIOUS INHIBITORS [J].
AGARWAL, RP ;
SPECTOR, T ;
PARKS, RE .
BIOCHEMICAL PHARMACOLOGY, 1977, 26 (05) :359-367
[3]   ECTO-5-'-NUCLEOTIDASE DEFICIENCY - ASSOCIATION WITH ADENOSINE-DEAMINASE DEFICIENCY AND NON-ASSOCIATION WITH DEOXYADENOSINE TOXICITY [J].
BOSS, GR ;
THOMPSON, LF ;
OCONNOR, RD ;
ZIERING, RW ;
SEEGMILLER, JE .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1981, 19 (01) :1-7
[4]  
BRUNS RF, 1986, MOL PHARMACOL, V29, P331
[5]  
CHECHIK BE, 1981, J IMMUNOL, V126, P1003
[6]   ADENOSINE, AN ENDOGENOUS ANTIINFLAMMATORY AGENT [J].
CRONSTEIN, BN .
JOURNAL OF APPLIED PHYSIOLOGY, 1994, 76 (01) :5-13
[7]  
DANG NH, 1990, J IMMUNOL, V144, P4092
[8]  
Dong RP, 1997, J IMMUNOL, V159, P6070
[9]  
Dong RP, 1996, J IMMUNOL, V156, P1349
[10]  
FOX RI, 1981, J IMMUNOL, V126, P2062